These three companies are healthcare leaders. They treat their shareholders well and offer promising growth prospects at attractive valuations. Consider buying them in 2025 to boost your dividend ...

Johnson & Johnson stock (NYSE: JNJ) lost about 7% in 2024, underperforming the broader S&P 500 index, which gained 23% for ...

Drugmaker AbbVie warned it will post a $3.5 billion impairment charge related to last year's $8.7 billion bet on Cerevel Therapeutics following the failure of the deal's key drug candidate, a ...

AbbVie Inc (ABBV) stock saw a decline, ending the day at $178.5 which represents a decrease of $-1.03 or -0.57% from the prior close of $179.53. The stock opened at $179.2 and touched a low of $176.18 ...

U.S. equities slumped at midday after the December jobs report came in higher than anticipated, putting more Federal Reserve rate cuts in doubt.

The merger combines two of the country's largest power generators as demand for electricity surges. Airline stocks have been doing well recently, and the results suggest that can continue. The ...

AbbVie said it would take a $3.5 billion dollar impairment charge related to the failure of a drug it acquired in its ...

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with ...

MoneyShow presents top investment ideas for 2024 from leading advisors. Part 2 includes Neo Performance Metals, Fannie Mae, ...

Investment analysts at Leerink Partnrs dropped their FY2024 EPS estimates for AbbVie in a research note issued to investors ...